Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,530,000 shares, an increase of 1,082.8% from the October 15th total of 213,900 shares. Based on an average trading volume of 2,330,000 shares, the days-to-cover ratio is presently 1.1 days. Currently, 11.5% of the shares of the company are sold short.

Iterum Therapeutics Stock Up 6.5 %

NASDAQ:ITRM traded up $0.09 during trading hours on Tuesday, hitting $1.48. 1,411,691 shares of the stock traded hands, compared to its average volume of 953,775. The stock has a 50 day moving average price of $1.13 and a 200 day moving average price of $1.25. The company has a market cap of $33.61 million, a price-to-earnings ratio of -0.70 and a beta of 2.25. Iterum Therapeutics has a 1 year low of $0.71 and a 1 year high of $2.50.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.22. Equities analysts forecast that Iterum Therapeutics will post -1.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Iterum Therapeutics in a research report on Tuesday, September 10th.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.